Terns Pharmaceuticals, Inc.
(TERN - NASDAQ)
52,95 USD
📋 Profilo Aziendale

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity.

|